View More Recent Stories

Apr 5, 2017 02:00AM OSE Immunotherapeutics Presented New Data at AACR* Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells and Inducing Antitumoral Potent T Memo

Mar 28, 2017 12:12PM OSE Immunotherapeutics SA: 2016 Results: Significant Milestones, First Profit, More Growth to Come

Mar 28, 2017 12:00PM 2016 Results: Significant Milestones, First Profit, More Growth to Come

Feb 21, 2017 04:37PM OSE Immunotherapeutics New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM) at the 24th Molecular Med TRI-CON 2017 Meeting

Feb 21, 2017 12:00PM OSE Immunotherapeutics New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM) at the 24Th Molecular Med TRI-CON 2017 Meeting

Feb 7, 2017 12:00PM OSE Immunotherapeutics to Present Corporate Overview at Upcoming BIO CEO & Investor Conference New York February 13-14, 2017

Jan 24, 2017 12:15PM OSE Immunotherapeutics Announces That the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Pivotal Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer

Jan 4, 2017 11:45AM OSE Immunotherapeutics to Present at Biotech Showcase™ 2017 Conference

Dec 6, 2016 11:45AM OSE Immunotherapeutics: Total Number of Voting Rights and Shares

Nov 28, 2016 11:45AM OSE Immunotherapeutics Appoints Dr. Frédérique Corallo, as Chief Medical Officer, Immunology

Nov 17, 2016 11:45AM OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology

Nov 15, 2016 11:45AM Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases

Nov 15, 2016 11:45AM Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases

Nov 15, 2016 02:00AM OSE Immunotherapeutics Awarded First Prize and "Listed Company" Prize as Part of 2016 Deloitte In Extenso Technology Fast 50 Ouest

Nov 4, 2016 12:45PM OSE Immunotherapeutics: Total Number of Voting Rights and Shares

Oct 24, 2016 11:45AM OSE Immunotherapeutics to Present at 2016 MedStart Up Days

Oct 4, 2016 11:45AM OSE Immunotherapeutics to Present the Preclinical Data of Its New Checkpoint Inhibitor Effi-DEM on SIRP-α/CD47 Strategic Pathway at the 2016 Immune Checkpoint Inhibitors Conference

Sep 20, 2016 11:45AM OSE Immunotherapeutics to Present Atalante 1, the Registration Clinical Trial of Tedopi®, Ongoing in the U.S. and in Europe, at the World Conference on Lung Cancer (WCLC)

Sep 15, 2016 11:45AM OSE Immunotherapeutics reinforces its Clinical Team with the Appointment of Iris Pauporté as Clinical Project Director

Sep 8, 2016 11:45AM OSE Immunotherapeutics Reports on First-Half 2016 Positive Financial Results Driven by Key Clinical Milestones

Sep 6, 2016 11:53AM OSE Immunotherapeutics: Total Number of Voting Rights and Shares

Feb 24, 2016 11:40AM OSE Pharma and Effimune Announce Proposed Merger to Create Significant Immunotherapy Player

View More Recent Stories